Molecular markers as risk factors for thyroid cancer
- 作者: Rogova M1, Novosad S1, Martirosian N1, Trukhina L1, Petunina N1
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- 期: 卷 91, 编号 10 (2019)
- 页面: 119-123
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33716
- DOI: https://doi.org/10.26442/00403660.2019.10.000357
- ID: 33716
如何引用文章
全文:
详细
作者简介
M Rogova
Sechenov First Moscow State Medical University (Sechenov University)аспирант каф. эндокринологии лечебного факультета Moscow, Russia
S Novosad
Sechenov First Moscow State Medical University (Sechenov University)аспирант каф. эндокринологии лечебного факультета Moscow, Russia
N Martirosian
Sechenov First Moscow State Medical University (Sechenov University)
Email: narinarine@list.ru
к.м.н., ассистент каф. эндокринологии лечебного факультета; ORCID: 0000-0002-0202-1257 Moscow, Russia
L Trukhina
Sechenov First Moscow State Medical University (Sechenov University)к.м.н., доц. каф. эндокринологии лечебного факультета; ORCID: 0000-0001-8997-4984 Moscow, Russia
N Petunina
Sechenov First Moscow State Medical University (Sechenov University)д.м.н., проф., зав. каф. эндокринологии лечебного факультета; ORCID: 0000-0001-9390-1200 Moscow, Russia
参考
- Бельцевич Д.Г., Ванушко В.Э., Мельниченко Г.А., Румянцев П.О., Фадеев В.В. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению (много)узлового зоба у взрослых (2015 год). Эндокринная хирургия. 2016;1(10):5-12. doi: 10.14341/serg201615-12
- Noone A.M, Cronin K.A, Altekruse S.F, Howlader N, Lewis D.R, Petkov V.I, Penberthy L. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-41. doi: 10.1158/1055-9965.EPI-16-0520
- Miki H, Oshimo K, Inoue H, et al. Diagnosis and surgical treatment of small papillary carcinomas of the thyroid gland. J Surg Oncol. 1993 Oct;54(2):78-80; discus. 80-1. doi: 10.1002/jso.2930540204
- Nikiforov Y.E. Thyroid tumors: Classification and general considerations. In: Nikiforov Y.E, Biddinger P.W, Thompson L.D.R, eds. Diagnostic pathology and molecular genetcis of the thyroid. Baltimore: Lippincott Williams & Wilkins, 2009. P. 94-102.
- Nikiforova M.N, Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19(12):1351-61. doi: 10.1089/thy.2009.0240
- Cibas E.S, Ali S.Z; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009 Nov;132(5):658-65. doi: 10.1309/AJCPPHLWMI3JV4LA
- Nikiforov Y.E, Ohori N.P, Hodak S.P, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-7. doi: 10.1210/jc.2011-1469
- Haugen B.R, Alexander E.K, Bible K.C, et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review
- Nikiforova M.N, Mercurio S, Wald A.I, Barbi de Moura M, Callenberg K, Santana dos Santos L, Gooding W.E, Yip L, Ferris R.L, Nikiforov Y.E. Analytical Performance of the ThyroSeq v3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules. Cancer. 2018. doi: 10.1002/cncr.31245
- Kimura E.T, Nikiforova M.N, Zhu Z, Knauf J.A, Nikiforov Y.E, Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC - RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-7.
- Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-62. doi: 10.1677/erc.1.0978
- Knauf J.A, Ma X, Smith E.P, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238-45. doi: 10.1158/0008-5472.CAN-05-0047
- Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88(9):4393-7. doi: 10.1210/jc.2003-030305
- Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-70. doi: 10.1158/1078-0432.CCR-06-1125
- Soares P, Trovisco V, Rocha A.S, et al. BRAF mutations and RET/ PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578-80. doi: 10.1038/sj.onc.1206706
- Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9):4197-205. doi: 10.1210/jc.2010-0337
- Xing M, Westra W.H, Tufano R.P, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-9. doi: 10.1210/jc.2005-0987
- Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow - up study. J Clin Endocrinol Metab. 2008;93(10):3943-9. doi: 10.1210/jc.2008-0607
- O’Neill C.J, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139-45, discus. 1145-6. doi: 10.1016/j.surg.2010.09.005
- Yip L, Nikiforova M.N, Carty S.E, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011
- Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321(1):86-93. doi: 10.1016/j.mce.2009.10.012
- Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16(2):240-5. doi: 10.1245/s10434-008-0233-3
- Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013 Aug 7;310(5):535. doi: 10.1001/jama.2013.8592
- Esapa C.T, Johnson S.J, Kendall-Taylor P, Lennard T.W, Harris P.E. Prevalence of RAS mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50(4):529-35. doi: 10.1046/j.1365-2265.1999.00704.x
- Basolo F, Pisaturo F, Pollina L.E, et al. N-RAS mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10(1):19-23. doi: 10.1089/thy.2000.10.19
- Adeniran A.J, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216-2. doi: 10.1097/01.pas.0000176432.73455.1b
- Zhu Z, Gandhi M, Nikiforova M.N, Fischer A.H, Nikiforov Y.E. Molecular profile and clinical - pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120(1):71-7. doi: 10.1309/nd8d-9laj-trct-g6qd
- Powell D.J.Jr, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid - type papillary carcinomas in murine thyroids. Cancer Res. 1998;58(23):5523-8.
- Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287-94.
- Nikiforov Y.E. RET/PTC Rearrangement in Thyroid Tumors. Endocr Pathol. 2002;13(1):3-16. doi: 10.1385/EP:13:1:03
- Sugg S.L, Ezzat S, Rosen I.B, Freeman J.L, Asa S.L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83(11):4116-22. doi: 10.1210/jcem.83.11.5271
- Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6. doi: 10.1210/jc.86.7.3211
- Saad A, Falciglia M, Steward D.L, Nikiforov Y.E. Amiodarone induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med. 2004;128(7):807-10. doi: 10.1043/1543-2165(2004)128<807:atatcc>2.0.co;2
- Mochizuki K, Kondo T, Nakazawa T, et al. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology. 2010;57(3):444-50. doi: 10.1111/j.1365-2559.2010.03646.x
- Kroll T.G, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289(5483):1357-60. doi: 10.1126/science.289.5483.1357
- Nikiforova M.N, Lynch R.A, Biddinger P.W, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318-26. doi: 10.1210/jc.2002-021907
- French C.A, Alexander E.K, Cibas E.S, et al. Genetic and biological subgroups of low - stage follicular thyroid cancer. Am J Pathol. 2003;162(4):1053-60. doi: 10.1016/S0002-9440(10)63902-8
- Ohori N.P, Nikiforova M.N, Schoedel K.E, et al. Contribution of molecular testing to thyroid fine - needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol. 2010;118(1):17-23. doi: 10.1002/cncy.20063
- Liu T, Wang N, Cao J, et al. The age - and shorter telomere - dependent TERT promoter mutation in follicular thyroid cell - derived carcinomas. Oncogene. 2014 Oct 16;33(42):4978-84. doi: 10.1038/onc.2013.446
- Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014 Sep 1;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094
- Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan A.K, Sun H, El Naggar A.K, Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603-10. doi: 10.1530/ERC-13-0210
- Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan A.K, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT Promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):1130-6. doi: 10.1210/jc.2013-4048
- Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi: 10.1038/ncomms3185
- Melo M, da Rocha A.G, Vinagre J, Batista R, et al. TERT Promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99:E754-E765. doi: 10.1210/jc.2013-3734